Talk:Pyridostigmine
| This is the talk page for discussing improvements to the Pyridostigmine article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||
| ||||||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Pyridostigmine.
|
first sentence
According to the Journal of Medical CBR Defense, Pyridostigmine does cross to the brain from the blood...ref http://www.jmedcbr.org/issue_0601/Cool/Cool_10_08.html "Pyridostigmine Crosses the Blood Brain Barrier to Induce Cholinergic and Non-Cholinergic Changes in Mouse Hypothalamus" —Preceding unsigned comment added by 170.3.8.253 (talk) 22:23, 17 June 2009 (UTC)
Other possible side affects: increased flatulence, insomnia, waking at irregular hours related to stomach cramps. — Preceding unsigned comment added by Dococsans6 (talk • contribs) 19:03, 1 February 2011 (UTC)
Growth hormone release
In https://www.ncbi.nlm.nih.gov/pubmed/1347008 a study has shown that Pyridostigmine "has been shown to elicit GH release when given alone and to potentiate the GH response to GH-releasing hormone (GHRH) in man." Until now, I havent't found other scholar studies, but it's being used off-label to enhance the GH release in humans.
I make this record to gather additional references before adding this use to the clinical uses section. --Cybermandrake (talk) 00:47, 7 April 2014 (UTC)